Blueprint Medicines | 4:持股变动声明-董事 COATS LONNEL
Blueprint Medicines | 144:拟议出售证券
Blueprint Medicines | 144:拟议出售证券
Blueprint Medicines | SC 13G/A:超过5%持股股东披露文件(修正)-T. ROWE PRICE ASSOCIATES, INC.(8.5%)
Blueprint Medicines | 4:持股变动声明-董事 Albers Jeffrey W.
Blueprint Medicines | 144/A:其他
Blueprint Medicines | 144:拟议出售证券
Blueprint Medicines | 10-Q:2024财年三季报
Blueprint Medicines | 8-K:Blueprint Medicinib 公布2024年第三季度业绩并上调了AYVAKIT® /AyvaKYT®(avapritinib)全年收入指引
Blueprint Medicines | 4:持股变动声明-高管 Namouni Fouad
Blueprint Medicines | 4:持股变动声明-董事 Albers Jeffrey W.
Blueprint Medicines | 144:拟议出售证券
Blueprint Medicines | 4:持股变动声明-高管 Landsittel Michael
Blueprint Medicines | 144:拟议出售证券
Blueprint Medicines | 4:持股变动声明-高管 Lee Philina
Blueprint Medicines | 144:拟议出售证券
Blueprint Medicines | 10-Q:2024财年二季报
Blueprint Medicines | 8-K:Blueprint Medicinib 公布2024年第二季度业绩并上调了AYVAKIT® /AYVAKYT®(avapritinib)全年收入指引
Blueprint Medicines | 4:持股变动声明-高管 Carter Percy H.
Blueprint Medicines | 4:持股变动声明-高管 Rossi Christina
暂无数据
暂无数据